Percutaneous transluminal angioplasty for lower limb ischaemia

Complications after Percutaneous Transluminal Angioplasty of Peripheral and Renal Arteries

This review deals with complications after percutaneous transluminal angioplasty (PTA). First some methodologic points are discussed. It seems important to standardize the way in which complications are reported. Our own complications in peripheral and renal PTA are summarized and taken as a basis for an analysis of various types of complications. Principally these may occur at different levels: at the puncture site, at the dilatation site as well as distant and general complications. To make comparisons with surgical series relevant it is suggested that all complications and mortality within 30 days are reported.

Exercise therapy or angioplasty? A summation analysis

OBJECTIVES

To compare the outcome of exercise therapy or angioplasty for the treatment of patients with intermittent claudication.

DESIGN

A summation analysis.

METHODS

A search using MEDLINE and PUBMED between 1966 and April 1999 followed by a review of the manuscripts yielded 54 studies involving angioplasty and 27 studies involving exercise therapy for intermittent claudication. Studies were only included (12 angioplasty and nine exercise series) when results were available for patients with intermittent claudication alone, and when outcome was assessed in terms of symptoms at a minimum of 6 months.

RESULTS

The total number of claudicants undergoing exercise therapy was 294 patients, with a mean symptomatic success rate of 38. 4% and a mean improvement in maximum walking distance of 189.7% at 6 months. The total number of claudicants undergoing angioplasty was 2071, with a mean overall symptomatic success rate of 76.6%. The mean overall complication rate was 9% and mean major complication rate was 2.7% for the angioplasty studies.

CONCLUSION

Although the result demonstrates an advantage of angioplasty over exercise therapy at 6 months, there is a small risk of major complications. However, comparison of studies was impaired due to disparity in patient numbers, limited follow-up time and lack of uniformity in outcome assessment. In order to achieve a valid comparison of these therapies in a future randomised study, a validated disease-specific instrument for the assessment of symptomatic outcome for claudicants is required.

Cumulative risk of bypass, amputation or death following percutaneous transluminal angioplasty

OBJECTIVE

To define cumulative risk of reconstruction, amputation or death following percutaneous transluminal angioplasty (PTA).

DESIGN

Non-randomised observational study.

PATIENTS AND METHODS

Two hundred and thirty-four PTAs in 212 patients. Minimum follow-up 6 months. Examination of data collected prospectively on manual card index. Examination of radiology and theatre ledgers over 2.5-year period. District Information System (Dis Data). Life-table analysis.

RESULTS

The cumulative risks of reconstruction at 12 months were 14.9% and 6.7%, respectively, following angioplasties below and above the inguinal ligament. Major and minor amputations were more common if the original lesions were below the inguinal ligament (relative risk (RR) 3.32, confidence interval (CI) CI 0.42-26.26 and RR 4.24, CI 0.055-32.9, respectively). They were also more likely in diabetic compared with non-diabetic patients (RR 9.95, CI 2.85-34.47 and RR 3.66, CI 1.28-10.44, respectively). No patient who presented with claudication underwent amputation. Death was more common in patients originally presenting with rest pain or gangrene than claudication (RR 3.94, CI 1.51-10.31).

CONCLUSION

This study confirms the poor outlook of diabetic patients with peripheral vascular disease or those presenting with rest pain, ulceration or gangrene. Percutaneous transluminal angioplasty was associated with approximately 80% limb salvage rate in those patients during the duration of the study.

Clinical outcome and restenosis following percutaneous transluminal angioplasty for ischaemic rest pain or ulceration

The role of percutaneous transluminal angioplasty in the management of severe leg ischaemia is controversial. To investigate further the efficacy of angioplasty and the clinical consequences of restenosis, a randomly selected cohort of 29 patients with ischaemic rest pain or ulceration was studied for 6 months after a technically successful balloon angioplasty. All patients had digital subtraction arteriography at the end of follow-up. Seven of 15 patients undergoing the procedure for rest pain had sustained relief from the initial dilatation. Partial or complete healing was noted in all 14 patients with ulceration and was maintained at 6 months in 11 despite significant (greater than 30 per cent) restenosis at the angioplasty site in eight. There were no complications or clinical deterioration associated with the procedure. Angioplasty is an effective method for treating the severely ischaemic leg, especially when used to achieve ulcer healing; restenosis is often clinically unimportant.

The significance of coumarin anticoagulation in laser assisted percutaneous transluminal angioplasty of femoropopliteal arterial obstructions

The optimal regime of drugs to prevent thrombocyte aggregation leading to reocclusion after percutaneous transluminal angioplasty (PTA) of peripheral vessels is not established. Both antiplatelet and antithrombotic drugs are prescribed. Prospective observations of two different anticoagulation regimes were made during an ongoing multicenter study of laser-assisted PTA (PTLA) of the femoropopliteal artery. Group I (129 patients) received coumarin at least during the first month, Group II (n = 71) did not get oral anticoagulation. Seventy-eight patients (61%) in Group I and 29 patients (47%) in Group II received platelet inhibitors. Groups I and II did not differ in baseline characteristics and PTLA complications (20.9 vs. 18.2%). Ankle brachial indices at 1, 3, 6 and 12 months were similar in both groups. This observational study does not provide evidence for superiority of oral anticoagulation in the management of patients undergoing PTLA of the femoropopliteal tract.

The place of percutaneous transluminal angioplasty in the treatment of patients having angiography for ischaemic disease of the lower limb

A prospective survey was made during 1 year of all 226 patients having angiography for lower limb ischaemia, to assess the accuracy of selection for angiography and the current treatment of the disease. Sixty-two percent of the patients presented with intermittent claudication and were found to have a fall in ankle systolic blood pressure on exercise. Thirty-one percent had rest pain or ischaemic skin changes. All patients had abnormal angiograms, with aorto-iliac disease present in 42%, combined with distal disease in 22%. There was a normal aorto-iliac segment in 58% of patients who had more distal disease. Calf-vessels only were affected in 15%. Treatment was by surgery only in 49%, and balloon dilatation only in 19%. A further 2% had dilatation as a complement to surgery, and 6% had surgery when dilatation failed or had complications. Dilatation was attempted unsuccessfully in 6%. No treatment was offered to 20% of patients. It is concluded that selection of patients for angiography using clinical and vascular laboratory assessment avoids unnecessary examinations and that approximately one-third of these selected patients are candidates for angioplasty, which is the preferred first option for treatment in all suitable patients.

The role of balloon angioplasty in the management of lower limb ischaemia

Three hundred and twenty-three angioplasties (159 iliac; 164 femoro-popliteal) were performed for lower limb ischaemia on 253 consecutive patients from 1980-86. The mean resting ankle/brachial pressure index (ABPI) was increased at one month in open angioplasties as follows: Femoro-popliteal 0.56-0.82; iliac with open superficial femoral artery (SFA) 0.7-0.95; iliac with occluded SFA 0.52-0.63. Successful angioplasty virtually abolished the post-exercise fall in ABPI except for patients having iliac dilations when multisegment disease was present. At 5 years, cumulative patency was 72% for iliac angioplasty and 53% for femoro-popliteal angioplasty. The results of angioplasty were compared with operative arterial reconstructions during 1985. Eighty-eight (91%) of 96 surgical bypasses were alive and patent at hospital discharge and 44 (71%) of 62 angioplasties were patent at 1 month. There were many fewer complications with angioplasty which involved a much shorter hospital stay (2 days vs 16 days).

A comparison of the costs of vascular surgery and balloon dilatation in lower limb ischaemic disease

The length of stay in hospital was recorded for 24 patients admitted for investigation and treatment of vascular disease of the lower limb and a detailed analysis of the costs incurred was made for 10 patients. It was found that the mean cost of angiography and surgery was pounds 1577 and of angiography and dilatation, pounds 301. The major factor in the cost difference was the shorter hospital stay for dilatation, with lesser factors being the use of fewer staff and the avoidance of general anaesthesia.